Clinical trials: Differentiated Thyroid Gland Carcinoma
Differentiated Thyroid Cancer
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
Patients diagnosed with thyroid cancer are commonly treated with surgery to remove their thyroid gland followed by radioiodine ablation to destroy any remaining parts of the thyroid gland that may have been missed during surgery.
- Trial name
- NCT00295763
- Testing
- Thyrogen (thyrotropin alfa for injection)
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 61 people
- Sponsor
- Genzyme, a Sanofi Company
Differentiated Thyroid Cancer (DTC)
A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China
The primary purpose of this study is to compare the progression-free survival (PFS) of participants with radioiodine (131 I)-refractory differentiated thyroid cancer (DTC) and radiographic evidence of disease progression within…
- Trial name
- NCT02966093
- Testing
- Lenvatinib
- Where
- 24 sites in China
- Volunteers
- 151 people
- Sponsor
- Eisai Co., Ltd.
Differentiated Thyroid Cancer, Pediatric Cancer
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy.
- Conditions
- Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
- Trial name
- NCT05783323
- Testing
- Larotrectinib monotherapy, 131I therapy
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital of Philadelphia
Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually…
- Conditions
- Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT02831179
- Testing
- Capecitabine, Temozolomide, Veliparib
- Sponsor
- Vanderbilt-Ingram Cancer Center
Differentiated Thyroid Cancer
Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
The study is designed to evaluate the clinical efficacy, safety and tolerability of selumetinib with radioactive iodine therapy in patients with differentiated thyroid cancer.
- Trial name
- ASTRA (NCT01843062)
- Testing
- Selumetinib, Radioactive Iodine Therapy
- Where
- 45 sites in United States, Brazil and 6 more
- Volunteers
- 233 people
- Sponsor
- AstraZeneca
Thyroid Nodule
Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.
According to the grades of echogenicity to evulated thyroid nodules is a subjective process and is thus influenced by the observer's judgement.
- Trial name
- NCT03700762
- Testing
- ultrasound gray-scale ratio
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- First People's Hospital of Hangzhou
Differentiated Thyroid Carcinoma
I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer
Thyroid nodules are a common clinical problem. Epidemiologic studies have shown the prevalence of palpable thyroid nodules to be approximately 5% in women and 1% in men living in iodine-sufficient parts of the world and up to 30%…
- Trial name
- CLERAD-PROBE (NCT01704586)
- Testing
- Radioiodine I-131, I-124
- Where
- 2 sites in Germany
- Volunteers
- 340 people
- Sponsor
- University of Wuerzburg
Differentiated Thyroid Cancer, Osteoporosis
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Postmenopausal women with differentiated thyroid cancer (DTC) taking suppressive doses of levothyroxine (L-T4) are thought to have accelerated bone loss and increased risk of osteoporosis.
- Trial name
- NCT02304757
- Testing
- 99Tc-MDP, Fosamax
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment.
- Conditions
- Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Follicular Carcinoma, Stage I Thyroid Gland Papillary Carcinoma
- Trial name
- NCT01811212
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma
Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer
This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites…
- Conditions
- Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
- Trial name
- NCT05575440
- Testing
- Computed Tomography, Fluorine F 18 Tetrafluoroborate, Positron Emission Tomography
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Microcarcinoma
Decision Aid Efficacy in Low Risk Thyroid Cancer
Low-risk thyroid cancer grows very slowly. More than 99% of patients with this cancer survive for at least 5 years. There are 3 main treatment options: remove the whole thyroid, remove just the part of the thyroid with the cancer…
- Conditions
- Differentiated Thyroid Cancer (DTC), Papillary Thyroid Microcarcinoma, Papillary Thyroid Carcinoma
- Trial name
- NCT07536412
- Testing
- Decision Aid
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Maryland, Baltimore
Radioiodine-refractory Differentiated Thyroid Cancer
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients
This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R…
- Trial name
- NCT07770074
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Differentiated Thyroid Cancer
Empirical Radioactive Iodine Therapy in DTC
The aim of the study is assessment the efficacy of empiric RAI therapy in DTC patients with elevated thyroglobulin levels and negative iodine scintigraphy.
- Trial name
- NCT07453225
- Testing
- Radioactive Iodine Therapy
- Volunteers
- 100 people
- Sponsor
- Assiut University
Ovarian Insufficiency, Radiation Exposure
Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer
Thyroid carcinoma is the most common endocrine malignancy. Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated.
- Trial name
- NCT04396158
- Testing
- radioactive iodine
- Volunteers
- 38 people
- Sponsor
- Assiut University
Thyroid Nodules
Realtime-Elastography (RTE) and Thyroid Nodules
The study is an open, prospective multicenter study. According to the statistical sample size calculation 593 patients with thyroid nodules ≥ 5mm in size will be included in the study.
- Trial name
- NCT01609946
- Testing
- Realtime-Elastography, linear ultrasound probe, Hitachi EUB-900, Japan, Cytology (FNAB) or Surgery
- Where
- 10 sites in Germany
- Volunteers
- 602 people
- Sponsor
- Johannes Vermehren
Differentiated Thyroid Cancer
A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.
This trial is a prospective, non-interventional, monocentric study aiming to collect standard of care imaging of patients treated with Iodine-131 for the determination of dosimetric studies.
- Trial name
- MEDIRAD (NCT03986437)
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Institut Claudius Regaud
Malignant Neoplasm of Thyroid Stage I, Malignant Neoplasm of Thyroid Stage II
Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer
Differentiated thyroid cancer is the most common neoplasm of endocrine system. After surgery and radioiodine treatment, thyroid stimulating hormone (TSH) suppression is the main goal which is achieved with levothyroxine…
- Trial name
- NCT01341886
- Testing
- Metformin
- Where
- Iran
- Volunteers
- 51 people
- Sponsor
- Mashhad University of Medical Sciences
Selenium Deficiency, Thyroid Cancer TNM Staging
Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma
Oxidative stress is involved in the pathogenesis of thyroid cancer, but the mechanism is not clear. The thyroid is the organ with the most abundant selenium content, and selenium may be involved in protecting the gland from the…
- Conditions
- Selenium Deficiency, Thyroid Cancer TNM Staging, Recurrence, Metastasis
- Trial name
- NCT04683575
- Testing
- Selenium Yeast
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Qianfoshan Hospital
Low Risk Differentiated Thyroid Cancer
Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
Open-label randomized phase III trial, using a non-inferiority comparison design. After randomization,patients will receive either post-operative radioiodine ablation with an activity of 1.1 GBq (30 mCi) after stimulation by…
- Trial name
- ESTIMABL2 (NCT01837745)
- Testing
- rhTSH stimulation, I131, Follow up
- Where
- France
- Volunteers
- 776 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris